Last update:
Weight management news
Tirzepatide outperformed semaglutide weight-loss drug results in real world patients, study shows
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become popular for weight loss, but results vary from person to person and from drug to drug. Venky Soundararajan and colleagues explored the full range of responses ...
7 hours ago
0
1
How the rise of weight-loss drugs could reshape food markets in the Global South
A new article published in Globalization and Health warns that the rapid rise of GLP-1 weight-loss drugs in high-income countries could have unintended consequences for food environments in low- and middle-income countries.
5 hours ago
0
0
Simple eating window can rival dietitian advice in pre-diabetes study
A major Australian clinical trial has found that timing when you eat can be just as effective as traditional dietitian-led advice in trying to lower the risk of developing type 2 diabetes.
14 hours ago
0
4
An economic case for teen weight-loss surgery
Metabolic and bariatric surgery for teens with severe obesity was found to be cost-effective over 10 years, according to a new analysis from Ann & Robert H. Lurie Children's Hospital of Chicago published in JAMA Network Open. ...
Jun 15, 2026
1
3
Tirzepatide may change how the body uses energy, trial suggests
Tirzepatide doesn't just help people lose weight; it also activates brown adipose tissue, representing a major milestone in obesity research, according to a study presented at ENDO 2026, the Endocrine Society's annual meeting ...
Jun 15, 2026
0
3
Tirzepatide GLP-1 medication may be most effective for weight loss
GLP-1 medications are marketed to help you lose weight, but one may be better at it than the rest, according to a new meta-analysis from the University of Georgia.
Jun 15, 2026
0
7
For adults with prediabetes, lifestyle intervention can lower risk of developing multiple chronic conditions
A clinical trial supported by the National Institutes of Health (NIH) found that adults with prediabetes assigned to a lifestyle intervention had a significantly lower risk of developing multiple chronic health conditions ...
Jun 15, 2026
0
1
Behavioral modifications like goal setting could lead to greater weight loss on tirzepatide
One of the largest real-world studies of people taking GLP-1 medications found women, those without pre-existing conditions such as type 2 diabetes and high blood pressure, and behavioral factors such as previously setting ...
Jun 15, 2026
0
2
Clinical trials suggest GLP-1s may improve fertility in men with obesity
GLP-1s do not harm male hormones or fertility after long-term use, according to a study being presented Monday at ENDO 2026, the Endocrine Society's annual meeting in Chicago. In fact, the research team found GLP-1s may improve ...
Jun 15, 2026
0
4
Obesity rewrites global heart disease trends, driving rising deaths in midlife and developing nations
Researchers are warning that obesity is reshaping the global cardiovascular disease crisis, as trend data covering 204 countries reveal that heart disease now peaks in people ages 50–54 rather than the elderly and increasingly ...
Jun 15, 2026
0
2
Visceral fat loss leaves 10-year 'metabolic legacy,' cutting diabetes risk by 28% despite weight regain
Lifestyle-induced loss of visceral fat (and not liver fat, pancreatic fat or subcutaneous fat) may have lasting health benefits years after the end of an intervention, even when body weight is fully regained, according to ...
Jun 14, 2026
0
13
Semaglutide linked to lower bone fracture risk
In people with type 2 diabetes, semaglutide was associated with a 15% reduction in bone fractures and greater weight loss compared with other anti-obesity medications, according to a study presented at ENDO 2026, the Endocrine ...
Jun 14, 2026
0
7
Could a once-a-day pill replace weight loss injections? Phase II oral GLP-1 drug trial shows promising results
For those scared of needles but who need GLP-1 receptor agonists to help manage their weight, there might be some good news. Researchers are testing a new oral, small-molecule GLP-1 receptor agonist called Elecoglipron, which ...
Study finds exercise decreases among people taking GLP-1 medication
Adults with obesity who lost weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased their physical activity, which is essential to protect muscle, according to a study presented at ...
Jun 13, 2026
0
8
Testosterone alone is not a replacement for lifestyle changes in older men at risk of type 2 diabetes, new study shows
Testosterone treatment may improve body composition, glucose metabolism and sexual desire in some older men at high risk of type 2 diabetes (T2D), but the benefits require engagement in a lifestyle program, according to a ...
Jun 13, 2026
0
4
ADA: Once-weekly cagrilintide + semaglutide promising in type 2 diabetes
Once-weekly cagrilintide, an amylin receptor agonist, plus semaglutide is efficacious for adults with type 2 diabetes inadequately controlled with diet and exercise, receiving metformin with or without a sodium glucose cotransporter ...
Jun 12, 2026
0
7
Why drinking alcohol makes you reach for chips and nachos
Have you ever wondered why savory foods like chips, nachos and salted nuts go so well with a beer or glass of wine? And why sometimes you feel an insatiable appetite for junk food while drinking?
Jun 12, 2026
0
8
Chile's food warning labels and ad bans cut child obesity risk, analysis suggests
Chile's complementary set of policies targeting food products high in fat, salt and sugar plausibly reduces the risk of school-age children being overweight or having obesity, finds a study published in The Lancet.
Jun 11, 2026
0
6
Consuming a moderate amount of carbs could lower cardiovascular risk while also keeping 'bad' cholesterol down
Many people cross bread, pasta and potatoes off their menus, hoping to drop pounds and improve their heart health. But there's a controversy behind this multibillion-dollar wellness phenomenon: Research is divided on carbohydrate-restricted ...
Jun 11, 2026
0
11
Injectable semaglutide shows early promise to improve fertility in women with PMOS
Researchers at the University of Colorado Anschutz have published a proof-of-concept study in Fertility and Sterility demonstrating that injectable semaglutide may offer meaningful reproductive benefits for women with polyendocrine ...
Jun 10, 2026
0
10
Hip dips: What are they and can you really get rid of them?
Hip dips are having a moment. The perfectly normal indentations that sit below your hips on the outer thigh have become the latest body feature to be scrutinized, fixed and agonized over on social media. But what are they? ...
Jun 10, 2026
0
4
Once-weekly survodutide linked to drop in body weight in obesity
For adults with obesity without diabetes, once-weekly survodutide, an investigational glucagon receptor-glucagon-like peptide-1 receptor dual agonist, is associated with greater reductions in body weight than placebo, according ...
Jun 10, 2026
0
4
New GLP-3 drug significantly slashes both weight and blood sugar levels in Phase III trial
Over the past few years, GLP-1 drugs have transformed the treatment landscape for obesity and type 2 diabetes. By mimicking a hormone that helps regulate blood sugar, slows digestion and curbs appetite, these medications ...
Brain mechanism reveals how food aroma primes metabolism and may explain obesity risk
Our brain prepares the body for an incoming meal before we even take the first bite. The aroma of food simmering on the stove, for instance, can trigger the brain to send signals to the pancreas, which in turn releases insulin ...
Jun 9, 2026
0
11
Drug apitegromab may stop muscle loss when taking weight loss drugs
A drug called apitegromab may help preserve lean body mass during weight loss with tirzepatide, a GLP-1 receptor agonist, according to a phase 2 clinical trial published in Nature Medicine. The findings suggest that blocking ...
Jun 9, 2026
0
6
